Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Sorafenib in advanced hepatocellular carcinoma.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group..

N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.

2.

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.

Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ.

J Clin Oncol. 2007 Jul 20;25(21):3055-60.

PMID:
17634483
3.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group..

N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.

4.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.

J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.

PMID:
16908937
5.

A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.

Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M, Baker SD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7. Epub 2006 Jun 23.

PMID:
16798122
6.

The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.

Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3612s-6s. Review.

7.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.

J Clin Oncol. 2006 Jun 1;24(16):2505-12. Epub 2006 Apr 24.

PMID:
16636341
8.

BAY 43-9006 inhibition of oncogenic RET mutants.

Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M.

J Natl Cancer Inst. 2006 Mar 1;98(5):326-34.

PMID:
16507829
9.

Raf: a strategic target for therapeutic development against cancer.

Beeram M, Patnaik A, Rowinsky EK.

J Clin Oncol. 2005 Sep 20;23(27):6771-90. Review.

PMID:
16170185
11.

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S.

J Clin Oncol. 2005 Feb 10;23(5):965-72. Epub 2004 Dec 21.

PMID:
15613696
12.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

13.

High-throughput determination of the free fraction of drugs strongly bound to plasma proteins.

Schuhmacher J, Kohlsdorfer C, Bühner K, Brandenburger T, Kruk R.

J Pharm Sci. 2004 Apr;93(4):816-30.

PMID:
14999720
14.

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ.

Ann Oncol. 2003 Dec;14(12):1783-90.

PMID:
14630685
15.

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

Hotte SJ, Hirte HW.

Curr Pharm Des. 2002;8(25):2249-53. Review.

PMID:
12369852
16.

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ.

J Clin Oncol. 2000 Jul;18(14):2780-7.

PMID:
10894879
17.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
18.

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL.

J Clin Oncol. 1998 May;16(5):1811-9.

PMID:
9586895
19.

Transection of the oesophagus for bleeding oesophageal varices.

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R.

Br J Surg. 1973 Aug;60(8):646-9. No abstract available.

PMID:
4541913
20.

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Charlson ME, Pompei P, Ales KL, MacKenzie CR.

J Chronic Dis. 1987;40(5):373-83.

PMID:
3558716

Supplemental Content

Support Center